CTLA4 and nasopharyngeal carcinoma: The promising high response rate observed for QL1706 in NPC is likely attributable to the contribution of the anti-CTLA-4 component, since NPC patients have been shown to have elevated infiltration of regulatory T cells in the tumor [34] and might be more sensitive to treatment with anti-CTLA-4 antibodies.